adenine has been researched along with Hematologic Malignancies in 28 studies
Excerpt | Relevance | Reference |
---|---|---|
"We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis." | 4.95 | Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. ( Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ, 2017) |
"This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations." | 2.87 | A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. ( Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J, 2018) |
" Furthermore, the nanoformulations studied to increase ibrutinib bioavailability are reported." | 2.72 | Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. ( Brullo, C; Russo, E; Spallarossa, A; Tasso, B; Villa, C, 2021) |
"Increased infections have been observed in patients taking ibrutinib." | 2.58 | Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. ( Pauff, JM; Satyanarayana, G; Talbott, M; Tillman, BF; Warner, JL, 2018) |
"Overall, AF and bleeding are manageable clinical events in patients receiving IB, not requiring drug interruption in most cases." | 2.58 | Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. ( Boriani, G; Corradini, P; Cuneo, A; Falanga, A; Foà, R; Gaidano, G; Ghia, PP; Marasca, R; Martelli, M; Massaia, M; Mauro, FR; Minotti, G; Molica, S; Montillo, M; Pinto, A; Tedeschi, A; Vitolo, U; Zinzani, PL, 2018) |
" phase I/II trials have been conducted to evaluate the dosing schedules and activity of this agent." | 2.58 | BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). ( He, W; Hu, H, 2018) |
" However, BTKi have a range of drug-drug and drug-food interactions, which may alter drug efficacy and/or increase toxicity." | 1.56 | Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management. ( Fancher, KM; Pappacena, JJ, 2020) |
"Low-grade bleeding was more common in ibrutinib-treated than comparator-treated patients (35% and 15%), and early low-grade bleeding was not associated with MH." | 1.51 | Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. ( Bista, A; Boornazian, L; Brown, JR; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Cramer, P; Cymbalista, F; Dilhuydy, MS; Dreyling, M; Ewer, MS; Fraser, G; Ghia, P; Graef, T; Jaeger, U; Liu, EY; Mahler, M; Moslehi, J; O'Brien, SM; Reddy, V; Rule, S; Shanafelt, TD; Treon, S; Valentino, R; Vempati, R; Yang, H, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 20 (71.43) | 24.3611 |
2020's | 8 (28.57) | 2.80 |
Authors | Studies |
---|---|
Egger, M | 1 |
Gornicec, M | 1 |
Wölfler, A | 1 |
Lembeck, AL | 1 |
Tinchon, C | 1 |
Maderdonner, M | 1 |
Prattes, J | 1 |
Kander, EM | 1 |
Zhao, Q | 1 |
Bhat, SA | 1 |
Hirsch, J | 1 |
Byrd, JC | 3 |
Ooka, L | 1 |
Wiczer, T | 2 |
Woyach, JA | 2 |
Awan, FT | 1 |
Rogers, KA | 2 |
Wang, TF | 1 |
Dickerson, T | 1 |
Waller, A | 1 |
Philippon, J | 1 |
Porter, K | 1 |
Haddad, D | 1 |
Guha, A | 1 |
Bhat, S | 1 |
Awan, F | 1 |
Addison, D | 1 |
Lewis, T | 1 |
Corcoran, DB | 1 |
Thurston, DE | 1 |
Giles, PJ | 1 |
Ashelford, K | 1 |
Walsby, EJ | 1 |
Fegan, CD | 1 |
Pepper, AGS | 1 |
Miraz Rahman, K | 1 |
Pepper, C | 1 |
Cordoba, R | 2 |
Fancher, KM | 1 |
Pappacena, JJ | 1 |
Danilov, AV | 1 |
Persky, DO | 1 |
Tazi, I | 1 |
Ciuculete, DC | 1 |
Popescu, RA | 1 |
Dan, GA | 1 |
Brullo, C | 1 |
Villa, C | 1 |
Tasso, B | 1 |
Russo, E | 1 |
Spallarossa, A | 1 |
Zhang, MY | 1 |
Zhu, GQ | 1 |
Zheng, JN | 1 |
Cheng, Z | 1 |
Van Poucke, S | 1 |
Shi, KQ | 1 |
Huang, HH | 1 |
Chen, FY | 1 |
Zheng, MH | 1 |
Schaffer, M | 1 |
Chaturvedi, S | 1 |
Davis, C | 1 |
Aquino, R | 1 |
Stepanchick, E | 1 |
Versele, M | 1 |
Liu, Y | 1 |
Yang, J | 1 |
Lu, R | 1 |
Balasubramanian, S | 1 |
Garside, J | 1 |
Healy, N | 1 |
Besson, H | 1 |
Hermans, R | 1 |
MacDougall, F | 1 |
Lestelle, D | 1 |
Diels, J | 1 |
Iraqi, W | 1 |
Chamilos, G | 1 |
Lionakis, MS | 1 |
Kontoyiannis, DP | 1 |
Snijder, B | 1 |
Vladimer, GI | 1 |
Krall, N | 1 |
Miura, K | 1 |
Schmolke, AS | 1 |
Kornauth, C | 1 |
Lopez de la Fuente, O | 1 |
Choi, HS | 1 |
van der Kouwe, E | 1 |
Gültekin, S | 1 |
Kazianka, L | 1 |
Bigenzahn, JW | 1 |
Hoermann, G | 1 |
Prutsch, N | 1 |
Merkel, O | 1 |
Ringler, A | 1 |
Sabler, M | 1 |
Jeryczynski, G | 1 |
Mayerhoefer, ME | 1 |
Simonitsch-Klupp, I | 1 |
Ocko, K | 1 |
Felberbauer, F | 1 |
Müllauer, L | 1 |
Prager, GW | 1 |
Korkmaz, B | 1 |
Kenner, L | 1 |
Sperr, WR | 1 |
Kralovics, R | 1 |
Gisslinger, H | 1 |
Valent, P | 1 |
Kubicek, S | 1 |
Jäger, U | 1 |
Staber, PB | 1 |
Superti-Furga, G | 1 |
Tillman, BF | 1 |
Pauff, JM | 1 |
Satyanarayana, G | 1 |
Talbott, M | 1 |
Warner, JL | 1 |
Hammond, SP | 1 |
Chen, K | 1 |
Pandit, A | 1 |
Davids, MS | 1 |
Issa, NC | 1 |
Marty, FM | 1 |
Boriani, G | 1 |
Corradini, P | 1 |
Cuneo, A | 1 |
Falanga, A | 1 |
Foà, R | 1 |
Gaidano, G | 1 |
Ghia, PP | 1 |
Martelli, M | 1 |
Marasca, R | 1 |
Massaia, M | 1 |
Mauro, FR | 1 |
Minotti, G | 1 |
Molica, S | 1 |
Montillo, M | 1 |
Pinto, A | 1 |
Tedeschi, A | 1 |
Vitolo, U | 1 |
Zinzani, PL | 1 |
He, W | 1 |
Hu, H | 1 |
de Jong, J | 1 |
Hellemans, P | 1 |
De Wilde, S | 1 |
Patricia, D | 1 |
Masterson, T | 1 |
Manikhas, G | 1 |
Myasnikov, A | 1 |
Osmanov, D | 1 |
Panizo, C | 1 |
de Zwart, L | 1 |
Snoeys, J | 1 |
Chauhan, V | 1 |
Jiao, J | 1 |
Sukbuntherng, J | 1 |
Ouellet, D | 1 |
Nastoupil, LJ | 1 |
Prasad, V | 1 |
Flowers, CR | 1 |
Mock, J | 1 |
Kunk, PR | 1 |
Palkimas, S | 1 |
Sen, JM | 1 |
Devitt, M | 1 |
Horton, B | 1 |
Portell, CA | 1 |
Williams, ME | 1 |
Maitland, H | 1 |
Brown, JR | 1 |
Moslehi, J | 1 |
Ewer, MS | 1 |
O'Brien, SM | 1 |
Ghia, P | 1 |
Cymbalista, F | 1 |
Shanafelt, TD | 1 |
Fraser, G | 1 |
Rule, S | 1 |
Coutre, SE | 1 |
Dilhuydy, MS | 1 |
Cramer, P | 1 |
Jaeger, U | 1 |
Dreyling, M | 1 |
Treon, S | 1 |
Liu, EY | 1 |
Chang, S | 1 |
Bista, A | 1 |
Vempati, R | 1 |
Boornazian, L | 1 |
Valentino, R | 1 |
Reddy, V | 1 |
Mahler, M | 1 |
Yang, H | 1 |
Graef, T | 1 |
Burger, JA | 1 |
Ezad, S | 1 |
Khan, AA | 1 |
Cheema, H | 1 |
Ashraf, A | 1 |
Ngo, DTM | 1 |
Sverdlov, AL | 1 |
Collins, NJ | 1 |
Prins, RC | 1 |
Burke, RT | 1 |
Tyner, JW | 1 |
Druker, BJ | 1 |
Loriaux, MM | 1 |
Spurgeon, SE | 1 |
Liu, N | 1 |
Hoogendoorn, S | 1 |
van de Kar, B | 1 |
Kaptein, A | 1 |
Barf, T | 1 |
Driessen, C | 1 |
Filippov, DV | 1 |
van der Marel, GA | 1 |
van der Stelt, M | 1 |
Overkleeft, HS | 1 |
Smithson, CR | 1 |
Schneider, SM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology[NCT04470947] | 150 participants (Anticipated) | Observational [Patient Registry] | 2020-06-10 | Recruiting | |||
Pharmacoscopy-guided Clinical Standard-of-care in Relapsed/Refractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial[NCT06138990] | 82 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients[NCT03096821] | 143 participants (Actual) | Observational | 2015-09-30 | Completed | |||
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
7 reviews available for adenine and Hematologic Malignancies
Article | Year |
---|---|
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials a | 2021 |
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chemistry, Pharmaceutical; COVID-19 Drug Treatment; Dr | 2021 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepa | 2017 |
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2018 |
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Topics: Adenine; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Hema | 2018 |
BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review).
Topics: Adenine; Apoptosis; Hematologic Neoplasms; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted The | 2018 |
Ibrutinib: a new targeted therapy for hematologic cancers.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Interactions; Hematologic Neoplasms; | 2015 |
6 trials available for adenine and Hematologic Malignancies
Article | Year |
---|---|
Hypertension and incident cardiovascular events following ibrutinib initiation.
Topics: Adenine; Aged; Antihypertensive Agents; Female; Heart Diseases; Hematologic Neoplasms; Humans; Hyper | 2019 |
PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
Topics: Adenine; Comparative Effectiveness Research; Data Collection; Databases, Factual; Hematologic Neopla | 2018 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hematologic Neoplasms; Hepatitis B; Hep | 2018 |
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Ibrutinib-related atrial fibrillation: A single center Australian experience.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Australia; Female; Hematologic Neoplasms; Hos | 2019 |
15 other studies available for adenine and Hematologic Malignancies
Article | Year |
---|---|
Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
Topics: Adenine; Animals; Antifungal Agents; Austria; Hematologic Neoplasms; Humans; Incidence; Invasive Fun | 2022 |
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Middl | 2019 |
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb | 2019 |
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocyt | 2021 |
Bringing hospital care closer to patients amidst COVID-19.
Topics: Adenine; Betacoronavirus; Checklist; Coronavirus Infections; COVID-19; Hematologic Neoplasms; Humans | 2020 |
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbid | 2020 |
[Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Topics: Adenine; Aniline Compounds; COVID-19 Drug Treatment; Drug Repositioning; Hematologic Neoplasms; Huma | 2021 |
Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Hematologic Neoplasms; Hemorrha | 2021 |
Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2018 |
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Topics: Adenine; Aged; Aged, 80 and over; Female; Fungi; Hematologic Neoplasms; Humans; Immunosuppressive Ag | 2018 |
The need to assess financial adverse events.
Topics: Adenine; Child; Costs and Cost Analysis; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperidin | 2018 |
Risk of Major Bleeding with Ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hematologic Neop | 2018 |
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Topics: Adenine; Aged; Female; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pipe | 2019 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Imm | 2013 |
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Hematologic Neoplasms; Humans; Molecular Probes; Nethe | 2015 |